Retavibart clinical trials
Also written TNM001.
How each study uses retavibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TNM001
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Zhuhai Trinomab Pharmaceutical Co., Ltd. (3)
Studies
Open first, then newest update. How each study uses retavibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk InfantsCompletedPhase 3Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT06710925Written as TNM001
- A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in InfantsCompletedPhase 2/3Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT06083623Written as TNM001
- A Study of TNM001 in Chinese Healthy Preterm and Term InfantsCompletedPhase 1/2Zhuhai Trinomab Pharmaceutical Co., Ltd.NCT05630573Written as TNM001
Codes
What other systems call retavibart · ClinicalTrials.gg INT016797
- UNII (FDA) HQ9W597Z73RETAVIBARTOne source FDA
- NCI Thesaurus C215759RetavibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HQ9W597Z73 | RETAVIBART | One source FDA |
| NCI Thesaurus | C215759 | Retavibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.